日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Out of Africa comes no support for global biodiversity catastrophes

非洲并未对全球生物多样性灾难提供任何支持。

Pimm, Stuart L; Davies, T Jonathan; Gittleman, John L

The future of medicine in a One Health world

在“同一健康”的世界中,医学的未来

Gittleman, John L

Implementing the Kunming-Montreal Biodiversity Targets

落实昆明-蒙特利尔生物多样性目标

Gittleman, John L; Pimm, Stuart L; Van Rensburg, Berndt J; Van Houtan, Kyle S; Roberts, Callum M

Global Diversity Patterns are Explained by Diversification Rates and Dispersal at Ancient, Not Shallow, Timescales

全球生物多样性模式可以用远古而非近古时间尺度上的物种分化速率和扩散来解释。

Stephens, Patrick R; Farrell, Maxwell J; Davies, T Jonathan; Gittleman, John L; Meiri, Shai; Moreira, Matthew O; Roll, Uri; Wiens, John J

The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials

美国食品药品监督管理局对一线晚期免疫肿瘤治疗肾细胞癌的试验中,根据反应深度对总生存期进行了汇总分析。

Chang, Elaine; Gittleman, Haley; Song, Chi; Bloomquist, Erik; Fernandes, Laura; Weinstock, Chana; Agrawal, Sundeep; Gormley, Nicole; Tang, Shenghui; Suzman, Daniel L; Amiri-Kordestani, Laleh; Pazdur, Richard; Kluetz, Paul G; McDermott, David F; Regan, Meredith M; Rini, Brian I

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

美国食品药品监督管理局批准摘要:Elacestrant 用于治疗雌激素受体阳性、人表皮生长因子受体 2 阴性、ESR1 突变的晚期或转移性乳腺癌

Shah, Mirat; Lingam, Hima; Gao, Xin; Gittleman, Haley; Fiero, Mallorie H; Krol, Danielle; Biel, Nikolett; Ricks, Tiffany K; Fu, Wentao; Hamed, Salaheldin; Li, Fang; Sun, Jillian Jielin; Fan, Jianghong; Schuck, Robert; Grimstein, Manuela; Tang, Liuya; Kalavar, Shyam; Abukhdeir, Abdelrahmman; Pathak, Anand; Ghosh, Soma; Bulatao, Ilynn; Tilley, Amy; Pierce, William F; Mixter, Bronwyn D; Tang, Shenghui; Pazdur, Richard; Kluetz, Paul; Amiri-Kordestani, Laleh

Interconnecting global threats: climate change, biodiversity loss, and infectious diseases

相互关联的全球威胁:气候变化、生物多样性丧失和传染病

Pfenning-Butterworth, Alaina; Buckley, Lauren B; Drake, John M; Farner, Johannah E; Farrell, Maxwell J; Gehman, Alyssa-Lois M; Mordecai, Erin A; Stephens, Patrick R; Gittleman, John L; Davies, T Jonathan

"One Health" needs ecology

“一体化健康”需要生态学

Gittleman, John L

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

FDA批准摘要:用于治疗转移性去势抵抗性前列腺癌的镥-177维匹伐肽四环素

Fallah, Jaleh; Agrawal, Sundeep; Gittleman, Haley; Fiero, Mallorie H; Subramaniam, Sriram; John, Christy; Chen, Wei; Ricks, Tiffany K; Niu, Gang; Fotenos, Anthony; Wang, Min; Chiang, Kelly; Pierce, William F; Suzman, Daniel L; Tang, Shenghui; Pazdur, Richard; Amiri-Kordestani, Laleh; Ibrahim, Amna; Kluetz, Paul G

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

FDA批准摘要:Mirvetuximab Soravtansine-Gynx用于治疗FRα阳性、铂类耐药卵巢癌

Dilawari, Asma; Shah, Mirat; Ison, Gwynn; Gittleman, Haley; Fiero, Mallorie H; Shah, Ankit; Hamed, Salaheldin S; Qiu, Junshan; Yu, Jingyu; Manheng, Wimolnut; Ricks, Tiffany K; Pragani, Rajan; Arudchandran, Arulvathani; Patel, Paresma; Zaman, Shadia; Roy, Arpita; Kalavar, Shyam; Ghosh, Soma; Pierce, William F; Rahman, Nam Atiqur; Tang, Shenghui; Mixter, Bronwyn D; Kluetz, Paul G; Pazdur, Richard; Amiri-Kordestani, Laleh